Stocks to Watch 04/17/2013, ACUR, OCZ, FDA rules on OxyContin, generic OxyContin, Generic Oxy

OCZ Technology Issues Update for Investors

SAN JOSE, CA--(Marketwired - April 17, 2013) -  OCZ Technology Group, Inc. (OCZ), a leading provider of high-performance solid-state drives (SSDs) for computing devices and systems, provides business update for the fourth quarter of 2013.
The Company is disclosing certain preliminary information about its fourth quarter of fiscal 2013 that ended on February 28, 2013, subject to certain closing procedures and further review by the Company and its auditors. As previously reported the Company estimated that revenue in each of the unreported quarters ending August 31, 2012 and November 30, 2012 is in the range of $65 million to $85 million. This range takes into effect the impact of the reclassification of certain customer costs from operating expenses to revenue, the significant reduction in channel inventory, the timing of revenue recognition and reserves for product returns. The preliminary revenue range for the unreported fourth quarter of fiscal 2013 is estimated to be between $65 million and $70 million. The Company also expects positive gross margins for the fourth quarter. This is an indication that the operating adjustments regarding restructuring and the restatement are behind the Company. Gross margins will continue to improve in the coming quarters due to the streamlining of products and focus on enterprise business. Operating expenses are estimated to be between $23 million and $26 million for the fourth quarter and include non-recurring restatement related charges of approximately $4 million which includes the completion of the internal investigation and other legal matters. The company's inventory levels also continued to improve as inventory on hand at the end of the fourth quarter was less than $50 million and channel inventory was at a 2-year low of less than $20 million.

Acura Pharmaceutical , ACUR

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its products include Oxecta Tablets CII, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, an over-the-counter immediate-release pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. The company has seven additional opioid products utilizing Aversion technology in various stages of development. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc., a wholly-owned subsidiary of Pfizer Inc. to develop and commercialize certain opioid analgesic products utilizing the company’s proprietary Aversion technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.

Source: company, OxBridge Research, Daily Stock Deals